PMID- 38434642
OWN - NLM
STAT- MEDLINE
DCOM- 20240305
LR  - 20240305
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 12
DP  - 2023
TI  - An early Indian experience with benralizumab - A compendium on severe asthma 
      cases: a case series.
PG  - 1225
LID - 10.12688/f1000research.132704.1 [doi]
LID - 1225
AB  - Background: Severe eosinophilic asthma (SEA), one of the phenotypes of asthma 
      that is characterized by elevated blood eosinophil counts, is a common cause of 
      uncontrolled asthma. Patients with SEA often experience severe persistent 
      symptoms and have frequent exacerbations despite optimal inhaler therapy. They 
      also have poor lung function and quality of life (QoL). Benralizumab (Fasenra), a 
      monoclonal antibody, has been approved for managing cases of SEA. This series of 
      six cases, the first of its kind from India, aims to add to the real-world 
      evidence of benralizumab in India. Methods: Benralizumab 30 mg (once in four 
      weeks for the first three doses followed by a dose every eight weeks for two 
      years) was administered in six patients with symptoms of cough, breathlessness on 
      exertion, and wheezing, diagnosed with SEA. The following were the endpoints 
      assessed: (i) overlap between high immunoglobulin E (IgE) and eosinophilic 
      asthma; (ii) reduction of exacerbations; (iii) withdrawal of oral 
      corticosteroids; and (iv) improvement in lung function and QoL. Results: In all 
      cases, management with benralizumab resulted in optimal clinical and functional 
      improvement, a decline in systemic steroid use, and improved QoL. Conclusions: 
      The cases presented here are the first of their kind in the Indian asthmatic 
      population with all SEA patients demonstrating significant improvement in 
      symptoms with the use of benralizumab.
CI  - Copyright: (c) 2023 Talwar D et al.
FAU - Talwar, Deepak
AU  - Talwar D
AUID- ORCID: 0000-0002-4733-7132
AD  - Pulmonology and Sleep Medicine, Metro Hospitals and Heart Institute, Noida, Uttar 
      Pradesh, 201301, India.
FAU - Yadav, Manoj
AU  - Yadav M
AD  - Pulmonology, Kailash Hospital, Centre for Respiratory Disease, Vadodara, Gujrat, 
      390007, India.
FAU - Maturu, Nagarjuna
AU  - Maturu N
AD  - Pulmonology, Yashodha Hospital, Hyderabad, Telangana, 500036, India.
FAU - Sharma, Rahul
AU  - Sharma R
AD  - Pulmonology, Yatharth Superspeciality Hospital, Noida, Uttar Pradesh, 201304, 
      India.
FAU - Meshram, Priti
AU  - Meshram P
AD  - Pulmonology Medicine, GGMC and JJ Hospital, Mumbai, Maharashtra, 400008, India.
FAU - Das, Soumya
AU  - Das S
AD  - Pulmonology, B.P Poddar Hospital and Medical Research Centre, Kolkata, West 
      Bengal, 700053, India.
LA  - eng
PT  - Journal Article
DEP - 20230927
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
RN  - 71492GE1FX (benralizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Humans
MH  - *Quality of Life
MH  - *Asthma/drug therapy
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antibodies, Monoclonal
PMC - PMC10904938
OTO - NOTNLM
OT  - Asthma
OT  - benralizumab
OT  - eosinophilia
OT  - interleukin-5
OT  - monoclonal antibodies
COIS- Competing interests: Benralizumab is produced by AstraZeneca. Financial support 
      has been received from AstraZeneca India only for manuscript development and 
      publication purposes. None of the authors have any competing interest to declare.
EDAT- 2024/03/04 06:42
MHDA- 2024/03/05 06:44
PMCR- 2023/09/27
CRDT- 2024/03/04 04:48
PHST- 2023/08/30 00:00 [accepted]
PHST- 2024/03/05 06:44 [medline]
PHST- 2024/03/04 06:42 [pubmed]
PHST- 2024/03/04 04:48 [entrez]
PHST- 2023/09/27 00:00 [pmc-release]
AID - 10.12688/f1000research.132704.1 [doi]
PST - epublish
SO  - F1000Res. 2023 Sep 27;12:1225. doi: 10.12688/f1000research.132704.1. eCollection 
      2023.